ECTRIMS 2019
Read the full Report (pdf)
European Committee for Treatment and Research in Multiple Sclerosis 11–13 September 2019, Stockholm, Sweden
Featured articles
Late-breaking: Ofatumumab versus teriflunomide in relapsing MS
CONTENTS
Online First
Towards a Comprehensive Assessment of MS Course
Cognitive assessment in MS
Tool to measure quality of life in MS
Novel ways to assess MS
Late-breaking: Role for CSF markers in autoimmune astrocytopathies
Targeted therapies for NMOSD in development
Monitoring and Treatment of Progressive MS
Challenges in diagnosing and treating progressive MS
Risk factors for conversion to secondary progressive MS
Transplantation of autologous mesenchymal stem cells
Siponimod delays time to wheelchair
Sustained reduction in disability progression with ocrelizumab
Late-breaking: Myelin-peptide coupled red blood cells
Optimising Long-Term Benefit of MS Treatment
Induction therapy over treatment escalation
Treatment escalation over induction therapy
Influence of age on disease progression
Exposure to DMTs reduces disability progression
Predicting long-term sustained disability progression
Treatment response scoring systems to assess long term prognosis
Late-breaking: Ofatumumab versus teriflunomide in relapsing MS
Safety Assessment in the Post-Approval Phase
Use of clinical registries in phase 4 of DMT
Genes, environment, and safety monitoring in using registries
Risk of hypogammaglobulinemia and rituximab
Determinants of outcomes for natalizumab-associated PML
Serum immunoglobulin levels and risk of serious infections
EAN guideline on palliative care
Pregnancy in the Treatment Era
The maternal perspective: when to stop/resume treatment and risks for progression
Foetal/child perspective: risks related to drug exposure and breastfeeding
Patient awareness about family planning represents a major knowledge gap
